-->

Tag: Braftovi

Home / Established Year

FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation
, , , , ,

Encorafenib with binimetinib is approved by the FDA for treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation

The Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as medicines that can be used to t..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy